The Access Committee proactively promotes public-private dialogues in order to achieve appropriate evaluation of the value of innovation and to improve Japanese patients’ access to drugs, such as 14-day limited prescription of new drugs, by investigating a cost effectiveness appraisal system that is aligned with the Japanese drug pricing system and by introducing overseas examples.
Materials for Access Committee Activities
- 2020/01/27 EFPIA Japan’s Basic Position on Cost-Effectiveness Assessment in Japan “Delivering Patient-Centered Innovation” (January 2020 ver.) get_app
- 2019/02/05 Cost-Effectiveness Analysis (CEA) in Japan: Basic Understanding and Implications for Japan “Putting the patients at the center of healthcare get_app
- 2015/09/16 EFPIA Viewpoint: Health Technology Assessment (HTA) Application in Select Markets and Implications for Japan get_app